Thanks, Steve. Our fourth quarter results exceeded the high end of our guidance ranges across all metrics, including record transaction value and adjusted EBITDA of $499.2 million and $36.7 million, respectively. P&C transaction value was up sequentially, in line with expectations and above normal seasonality, driven by higher year-over-year pricing and volumes as investment in our marketplace continued to scale. Transaction value in our health vertical was down 8% year-over-year, slightly below our expectations, as we saw softening in under-65, as well as the expected headwinds in Medicare Advantage. For 2024, our health vertical accounted for $270 million of transaction value or 18% of the total, at a 14% take rate. Within health, under-65 accounted for approximately two-thirds of the transaction value at a slightly higher take rate. Our Q4 adjusted EBITDA included $9 million of add backs related to the FTC matter. These consisted of $2 million of legal expenses, along with a $7 million reserve recorded in accordance with U.S. GAAP requirements. Inclusive of these add backs, Q4 adjusted EBITDA increased $24 million year-over-year, representing 189% growth. Looking forward to Q1, we expect P&C transaction value levels to grow approximately 170% year-over-year, representing a high single digit sequential decline. To-date, we have seen a moderation in pricing from Q4 levels, partially offset by the typical seasonal volume uplift and we expect these trends to continue for the remainder of the quarter. In our health vertical, we expect transaction values to decline by a high-teens percentage year-over-year, as conditions in under 65 have continued to soften in Q1. As Steve mentioned, we see our long-term growth opportunity in this vertical in Medicare Advantage. Moving to our consolidated financial guidance, we expect Q1 transaction value to be between $415 million and $440 million, a year-over-year increase of 95% at the midpoint. We expect revenue to be between $225 million and $245 million, a year-over-year increase of 86% at the midpoint. We expect adjusted EBITDA to be between $24.5 million and $26.5 million, a year-over-year increase of 77% at the midpoint. We expect overhead to increase sequentially by approximately $500,000 to $1 million, as we continue to selectively add headcounts to support and drive growth. Turning to the balance sheet, we’ve made solid progress in deleveraging, ending the quarter with $43 million of cash and net debt to 2024 adjusted EBITDA of less than 1.3 times. Moving forward, we expect to convert the significant portion of adjusted EBITDA into unlevered free cash flow due to the operating efficiencies in our business, including minimal capital expenditures and low working capital needs. With that, Operator, we are ready for the first question.